Novo Nordisk designed the ten trial Phase III PIONEER program to support the NDA for oral semaglutide for the treatment of type 2 diabetes. If approved, semaglutide will be the first oral GLP-1 receptor agonist and will likely become a preferred treatment to add to patients that are inadequately controlled with metformin. There are links to seven published studies in the Pharmaceutical Pipeline Tracker.
Following are summaries of what we know about the ten trials.
Comments are closed.
|
Stay informed, subscribe to the
Prescribe Right Pharmaceutical Pipeline Tracker Latest Tweets from Prescribe Right
Archives
May 2023
|
Services |
Company |
|
© COPYRIGHT 2015. ALL RIGHTS RESERVED.
|